BIRC2 and breast carcinoma: We found that cIAP1 downregulation tended to increase susceptibility to TRAIL in CAMA-1 cells, suggesting that degradation of cIAP1 is an important step in the LCL-161 potentiation of TRAIL and that cIAP1, in line with other cell types, have an anti-apoptotic role in TRAIL signaling also in breast cancer cells.